Key Highlights
- The INTerpath-001 Phase 3 study successfully achieved its primary goal of recurrence-free survival in melanoma patients treated with Merck and Moderna’s experimental therapy
- Researchers enrolled 1,137 participants with high-risk Stage IIB-IV melanoma in what represents the first successful large-scale Phase 3 trial for an mRNA cancer vaccine
- Shares of MRK climbed to $143.52 during premarket hours, representing approximately 10% gains and establishing a new 52-week peak
- Moderna’s stock price exploded more than 90% in premarket activity, reaching $118.61
- Financial analysts at Barclays project the treatment could produce roughly $3 billion in melanoma-related revenue by 2035
Shares of Merck experienced a significant surge of approximately 10% during Wednesday’s premarket session following the pharmaceutical giant’s announcement alongside Moderna of a groundbreaking achievement in their collaborative mRNA cancer vaccine program.
The collaborative INTerpath-001 Phase 3 clinical study evaluating Intismeran autogene in combination with Keytruda successfully achieved both its primary goal of recurrence-free survival and its secondary objective of distant metastasis-free survival among patients with completely resected Stage IIB-IV melanoma.
During premarket activity, MRK touched $143.52, establishing a fresh 52-week peak and surpassing its previous high of $137.98.
The clinical investigation included 1,137 high-risk participants who underwent surgical melanoma removal. Trial participants were administered up to nine doses combining Keytruda with the personalized vaccine, or received Keytruda monotherapy, over roughly one year. Researchers observed no unexpected safety concerns.
This achievement represents the first successful late-stage clinical trial for an mRNA-based cancer vaccine and the inaugural study demonstrating superior efficacy compared to Keytruda monotherapy in this specific patient population.
These findings build upon encouraging Phase 2b data released in January, demonstrating that the combination therapy decreased the risk of disease recurrence or death by 49% over five years when compared to Keytruda alone.
Moderna experienced a dramatic surge exceeding 90% during premarket trading following the announcement, reaching $118.61. The biotech company became the most-discussed stock on Stocktwits after the news broke.
Regulatory Conversations on the Horizon
Dean Li, head of research and development at Merck, indicated during a CNBC interview that both companies anticipate initiating regulatory discussions in the coming months. Moderna’s CEO Stephane Bancel clarified that pricing considerations remain undecided, emphasizing the data only became available recently.
Bancel highlighted that Intismeran differs from certain cell therapies as it doesn’t utilize patients’ own cells, potentially enabling broader manufacturing capabilities and more favorable cost structures.
Financial analysts at J.P. Morgan emphasized that the vaccine’s commercial launch for adjuvant melanoma treatment will prove critical for Moderna’s path back to profitability. Barclays researchers forecast the therapy could generate approximately $3 billion in melanoma-specific sales by 2035.
Wall Street Upgrades Provided Additional Momentum
The positive clinical announcement followed a series of favorable analyst revisions. Daiwa elevated MRK to Outperform from Neutral on August 17, highlighting pipeline advancement. Wells Fargo initiated coverage with a Buy rating on the same date.
William Blair analyst Myles Minter observed that the interim findings position both pharmaceutical companies favorably for pursuing regulatory authorization, noting the data appears promising for ongoing investigations across additional cancer types. Further Phase 3 studies examining non-small cell lung cancer continue patient enrollment.
The overall equity market showed minimal movement on Wednesday, with the S&P 500 advancing just 0.1% and the Nasdaq posting slight losses, indicating MRK’s rally was driven entirely by company-specific catalysts.
Merck is presently trading at its new 52-week high of $143.52 as of Wednesday’s premarket session.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
